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Background. Many HIV-infected children are initiated on antiretroviral therapy (ART) during hospitalisation in South Africa (SA). No 
published data on these outcomes exist.
Objectives. To assess the short-term outcomes of children initiated on ART in the intensive care unit (ICU), general medical wards 
(GMWs) and outpatient HIV clinics (OHCs) at Red Cross War Memorial Children’s Hospital (RCWMCH), Cape Town, SA.
Methods. We conducted a retrospective cohort study of HIV-infected children aged <13 years commenced on first-line ART between 
January 2008 and December 2011. Outcomes included death, virological suppression and changes in CD4 count. Kaplan-Meier estimates, 
multivariate Cox proportional hazard ratios and logistic regression were used to estimate outcomes at 6 months.
Results. One hundred and six children were commenced on ART in the ICU, 509 in the GMWs and 127 in the OHCs; 65.7% of all children 
were <12 months old. Of children qualifying for rapid ART initiation according to the 2013 national treatment guidelines, 182 (24.9%) 
started therapy within 7 days of diagnosis. Overall mortality was 6.4% (95% confidence interval (CI) 4.9 - 8.4). Of children remaining in 
care at RCWMCH, 51.0% achieved a CD4 percentage ≥25% and 62.3% a viral load ≤50 copies/mL 6 months after ART initiation. Mortality 
was higher in the ICU cohort (13.2%) than in the GMW and OHC cohorts (5.5% and 3.9%, respectively, log-rank p=0.004). Predictors 
of mortality included moderate underweight (adjusted hazard ratio (aHR) 2.4; 95% CI 1.1 - 5.2), severe underweight (aHR 3.2; 95% CI 
1.6 - 6.5), absence of caregiver counselling sessions (aHR 2.9; 95% CI 1.4 - 6.0) and ART initiation in the ICU (aHR 2.6; 95% CI 1.4 - 4.9).
Conclusion. These results highlight the importance of understanding the context in which children are initiated on ART, when comparing 
outcomes in different settings.
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The majority of HIV-infected children manifest clinical 
features of disease by 12 months of age.[1,2] A pooled 
analysis of HIV-infected children living in Africa showed 
that without optimal therapy 35.2% and 52.5% died by 
12 and 24 months of age, respec tively.[3] Conversely, the 
Children with HIV Early Antiretroviral Therapy (CHER) Study showed that 
if antiretroviral therapy (ART) was commenced during the first 3 months 
of life in asymptomatic HIV-infected infants with limited immunological 
suppression, mortality risk was reduced by 76% and disease progression by 
75%.[4] Consequently, treatment programmes have progressively increased 
access to universal ART for infected children. In South Africa (SA), ART for 
all HIV-infected children aged <12 months was implemented in December 
2009.[5] In March 2013, this policy was extended to all HIV-infected children 
aged <5 years, and expedited initiation of ART within 7 days of HIV 
diagnosis was recommended for all infants and older children with advanced 
clinical disease and/or severe immunosuppression.[6]
Although these policy changes encouraged increased access to ART, 
treatment coverage has remained relatively low in SA, resulting in high 
hospitalisation rates among HIV-infected children due to severe comorbidity. 
At the end of 2012, an estimated 63% of 220 000 children <15 years 
of age who required therapy were actually receiving ART in SA.[7] The 
majority of HIV-infected children requiring hospitalisation at Red Cross 
War Memorial Children’s Hospital (RCWMCH), Cape Town, are ART-naïve 
infants, including many young infants. The median age of 1 360 children 
initiated on ART at RCWMCH during a 6-year period was 8 months, and 
25% were ≤3 months of age.[8] Because the majority are infants with severe 
comorbidity, initiating ART during hospitalisation is a common clinical 
practice at RCWMCH.[9] With the advent of the 2013 national guidelines, it 
is likely that increas ing numbers of young HIV-infected infants and children 
at other healthcare facilities across SA are being initiated on ART during 
hospitalisation. No published local studies have reported the outcomes of 
children initiated on ART during hospitalisation. To address this question, 
we examined the short-term outcomes of children initiated on ART in the 
intensive care unit (ICU), general medical wards (GMWs) and outpatient 
HIV clinics (OHCs) at RCWMCH.
Methods
Study location
This study was undertaken at RCWMCH, a tertiary referral hospital 
dedicated to the care of children up to 13 years of age. This includes 
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Table 1. Characteristics of HIV-infected children prior to ART initiation*
Overall patient baseline 
characteristics
Patient characteristics stratified according to ART initiation location
OHCs GMWs ICU p-value
Age (months), median (IQR) N=749
5 (3 - 23)
N=127
22 (5 - 71)
N=509
5 (3 - 21)
N=106
3 (3 - 4)
0.0001
Age categories (months), n (%) N=749 N=127 N=509 N=106 0.0001
<3 130 (17.4) 14 (11.0) 90 (17.7) 25 (23.6)
3 - 12 362 (48.3) 37 (29.1) 247 (48.5) 72 (67.9)
13 - 60 147 (19.6) 39 (30.7) 102 (20.047) 6 (5.7)
>60 110 (14.7) 37 (29.1) 70 (13.8) 3 (2.8)
Gender, n (%) N=749 N=127 N=510 N=106 0.61
Female 379 (50.6) 60 (47.2) 258 (50.6) 57 (53.8)
Male 370 (49.4) 67 (52.8) 252 (49.4) 49 (46.2)
WAZ, median (IQR) N=700
–2.14 (–3.42 - –0.95)
N=115
–1.14 (–2.47 - –0.23)
N=477
–2.33 (–3.56 - –1.17)
N=102
–2.48 (–3.91 - –1.37)
0.0001
WAZ categories, n (%) N=700 N=115 N=477 N=102 0.0001
Mild-normal 331 (47.3) 82 (71.3) 210 (44.0) 47 (46.1)
Moderate underweight 141 (20.1) 14 (12.2) 109 (22.9) 17 (16.7)
Severe underweight 228 (32.6) 19 (16.5) 167 (35.0) 38 (37.3)
HAZ, median (IQR) N=525
–2.14 (–3.55 - –0.95)
N=121
–1.92 (–2.84 - –0.91)
N=338
–2.16 (–3.7 - –1.1)
N=61
–2.00 (–3.72 - –0.2)
0.20
HAZ categories, n (%) N=525 N=121 N=338 N=61 0.02
Mild-normal 248 (47.2) 63 (52.1) 153 (45.8) 30 (49.2)
Moderate stunting 110 (201.0) 34 (28.1) 64 (18.9) 10 (16.4)
Severe stunting 167 (31.8) 24 (19.8) 120 (35.5) 21 (34.4)
WHZ, median (IQR) N=446
–1.2 (–2.61 - –0.04)
N=83
–0.04 (–1.29 - –0.8) 
N=297
–1.53 (–2.8 - –0.3)
N=61
–1.37 (–2.82 - –0.31)
0.0001
WHZ categories, n (%) N=446 N=81 N=297 N=61 0.0001
Mild-normal 293 (65.7) 72 (88.9) 180 (60.6) 37 (60.7)
Moderate wasting 70 (15.7) 7 (8.6) 50 (16.8) 12 (19.7)
Severe wasting 83 (18.6) 2 (2.5) 67 (22.6) 12 (19.7)
CD4 percentage, median (IQR) N=742
17.00 (10.0 - 24.6)
N=127
17.6 (10.4 - 24.4)
N=509
17.12 (10 - 25.3)
N=106
14.35 (8.9 - 22.5)
0.12
CD4 percentage, n (%) N=742 N=127 N=509 N=106 0.27
≤25% 180 (24.3) 29 (22.8) 132 (25.9) 19 (17.9)
>25% 562 (75.7) 98 (77.2) 377 (74.1) 87 (82.1)
VL, n (%) N=691 N=123 N=465 N=96 0.0001
≤100 000 183 (26.5) 58 (47.2) 109 (23.4) 15 (15.6)
>100 000 508 (73.5) 65 (52.9) 356 (76.6) 81 (84.4)
WHO stage, n (%) N=741 N=127 N=502 N=106 0.0001
Stage 1 39 (5.3) 9 (7.1) 29 (5.8) 1 (1.0)
Stage 2 62 (8.4) 19 (15.0) 40 (8.0) 3 (2.8)
Stage 3 258 (34.8) 68 (53.5) 182 (36.3) 6 (5.7)
Stage 4 382 (51.6) 31 (24.4) 251 (50.0) 96 (90.6)
TB disease, n (%) N=743 N=127 N=504 N=105 0.0001
None 558 (75.1) 82 (64.6) 380 (75.4) 89 (84.8)
PTB 133 (17.9) 33 (26.0) 87 (17.3) 6 (5.7)
EPTB 15 (2.0) 8 (6.3) 10 (1.98) 4 (3.8)
PTB + EPTB 37 (5.0) 4 (3.1) 27 (5.4) 6 (5.7)
Continued ...
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inpatient care, intensive care and outpatient 
follow-up for HIV-infected children.
Study design, inclusion criteria and 
baseline data collection
A retrospective cohort study was conducted. 
Children <13 years of age commenced on first-
line ART between January 2008 and December 
2011 at RCWMCH were included. Data were 
extracted from the ART Microsoft Access 
database. Additional baseline patient clinical 
information and maternal information were 
extracted retrospectively from hospital records. 
Data collected prior to starting ART included 
age, gender, CD4 percentage and absolute 
count, plasma HIV RNA concentration 
(viral load (VL)), growth status, World 
Health Organization (WHO) clinical stage, 
the presence of active tuberculosis (TB), and 
the time interval between HIV diagnosis and 
ART initiation. Ages were grouped into one 
of four categories: <3 months, 3 - 12 months, 
13 - 60 months and >60 months. Mass and 
length/height measurements were transformed 
into weight-for-age z-scores (WAZ), height-
for-age z-scores (HAZ) and weight-for-height 
z-scores (WHZ) using the WHO 2006 Child 
Growth Standards.[10] Moderate underweight, 
stunting and wasting were defined as WAZ, 
HAZ and WHZ between –2 and –3, and severe 
underweight, stunting and wasting as WAZ, 
HAZ and WHZ below –3. Primary baseline 
clinical conditions were defined as the disease 
process that probably contributed to hospital 
admission, as determined by the attending 
clinician. Extrapulmonary TB (EPTB) for the 
purpose of this analysis was defined as a patient 
with TB involving organs other than the lungs 
such as pleura, pericardium, lymph nodes, 
abdomen, joints and bones and meninges. 
Patients were stratified into one of three groups 
based on the site of ART initiation, i.e. ICU, 
GMWs or OHCs.
Counselling of caregivers by trained 
paediatric ART counsellors prior to ART 
initiation is usually practised at RCWMCH. 
The aim is to impart the knowledge and 
skills needed to provide treatment to their 
children. Three counselling sessions, each 
covering different aspects of the disease 
process, practical issues around treatment, 
and a formal demonstration in administering 
ART to affected children on an individualised 
basis, are provided before and during the 
course of ART initiation. These sessions are 
documented on a prescribed checklist.
Study outcomes
Outcome measures included death, loss to fol-
low-up (LTFU), attrition, virological suppres-
sion and changes in CD4 count and percentage. 
Outcomes were evaluated at 6 months using 
the measure taken closest to 6 months after ini-
tiation, within a window of 3 - 9 months after 
ART initiation. LTFU was defined as failure to 
attend a follow-up visit within 3 months after 
the last scheduled appointment was missed. 
Attrition was defined as a combination of 
patients who had died and those who were 
LTFU during the study period.
Outcomes of those transferred out were 
determined using linkage with the Western 
Cape provincial laboratory database and 
Table 1. (continued) Characteristics of HIV-infected children prior to ART initiation*
Overall patient baseline 
characteristics
Patient characteristics stratified according to ART initiation location
OHCs GMWs ICU p-value
Time to ART initiation relative to TB rx 
initiation (days), median (IQR)
N=173
12 (24 - 1)
N=43
29 (92 - 16)
N=114
9 (16 - 2)
N=16
–6.5 (3 - –16)
0.0001
Time to ART initiation relative to HIV 
dx (days), median (IQR)
N=648
13 (7 - 38.5)
N=100
48 (26 - 250.5)
N=445
12 (7 - 28)
N=97
5 (3 - 9)
0.0001
Time to ART initiation relative to 
hospital admission (days), median (IQR)
N=749
7 (3 - 11)
N=127
NA
N=510
8 (6 - 13)
N=106
5 (3 - 7)
0.0001
IQR = interquartile range; PTB = pulmonary TB; rx = treatment; dx = diagnosis; NA = not applicable.
*In Table 1, non-normally distributed continuous variables were analysed using the Kruskal-Wallis non-parametric test. The χ2 test of association and Fisher’s exact test were used to test associations 
between categorical variables.
Table 2. Characteristics of caregivers of HIV-infected children prior to ART initiation*
Overall 
baseline 
caregiver 
characteristics 
Caregiver characteristics stratified 
according to ARV initiation location
OHCs GMWs ICU p-value
Reported maternal HIV status  
at ART initiation, n (%)
N=749 N=127 N=509 N=106 0.1
Positive 540 (72.1) 103 (81.1) 358 (70.3) 72 (67.9)
Negative 46 (6.1) 4 (3.2) 32 (6.3) 10 (9.4)
Unknown 163 (21.8) 20 (15.8) 119 (23.4) 24 (22.6)
Maternal MTCT prophylaxis, 
n (%)
N=749 N=127 N=509 N=106 0.05
Yes 258 (34.5) 43 (33.9) 164 (32.2) 46 (43.4)
No 353 (47.1) 68 (53.5) 243 (47.7) 40 (37.7)
Unknown 138 (18.4) 16 (12.6) 102 (20.0) 20 (18.9)
Maternal ART at ART 
initiation, n (%)
N=749 N=127 N=509 N=106 0.33
Yes 98 (13.1) 21 (16.5) 67 (13.2) 9 (8.5)
No 487 (65.0) 85 (66.9) 325 (63.9) 70 (66.0)
Unknown 118 (15.7) 10 (7.9) 94 (18.5) 15 (14.2)
NA 46 (6.1) 11 (8.7) 23 (4.5) 12 (11.1)
Primary caregiver status, n (%) N=749 N=127 N=509 N=106 0.004
Mother 647 (86.4) 104 (81.9) 435 (85.8) 101 (95.3)
Other 69 (9.2) 18 (14.2) 50 (9.9) 1 (0.9)
None 33 (4.4) 5 (3.9) 24 (3.9) 4 (3.8)
MTCT = mother-to-child transmission; NA = not applicable.
*In Table 2 the χ2 test of association and Fisher’s exact test were used to test associations between categorical variables.
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folder reviews. Mortality ascertainment was based on death docu-
mented in the RCWMCH folder, usually after re-presenting and 
being admitted to RCWMCH. Children who had specimen results 
of any nature recorded on the National Health Laboratory Service 
database at 6 months after ART initiation were considered alive. 
Children with no record of specimen results after transfer out and 
who were not documented to have died by 31 March 2013 were 
assumed to be LTFU.
Two cut-off values were used to define virological suppression, i.e. 
a VL of <400 copies/mL or <50 copies/mL. HIV RNA measurements 
were performed using Abbott Realtime HIV-1 assay and CD4 
measurements by the PanLeucogated method.[11,12]
Statistical analysis
Pre-ART continuous variables were non-normally distributed and 
therefore compared using the Kruskal-Wallis test. Frequencies 
and proportions were used to describe pretreatment categorical 
variables. The χ2 test of association or Fisher’s exact test was used 
to assess associations between these variables. CD4 percentage and 
VL results at 6 months were compared with the respective baseline 
results using the Wilcoxon signed-rank test for paired samples. 
Kaplan-Meier curves were fitted to estimate mortality, LTFU and 
attrition probabilities during the first 6 months of ART.
Multivariable Cox proportional hazards regression was used to 
assess factors associated with mortality, LTFU and attrition during 
the first 6 months of ART, adjusting for pretreatment clinical and 
demographic variables. Logistic regression was used to assess factors 
associated with an unsuppressed VL during the first 6 months of ART, 
i.e. plasma HIV RNA concentration >400 copies/mL or >50 copies/
mL, adjusting for pretreatment clinical and demographic variables. 
Variables with p-values of <0.1 on univariate analysis were included 
in the regression models.
The data were analysed using the STATA Release 12.0 statistical 
software package (STATACorp, College Station, USA).
Ethical considerations
The study was conducted in accordance with the Declaration 
of Helsinki, and was approved by the Human Research Ethics 
Committee, Faculty of Health Sciences, University of Cape Town 
(reference number: HREC REF: 261/2002).
Results
In total, 878 children were treated with ART at RCWMCH during 
the study period. Of these, 129 were excluded from the analysis: 101 
were ART experienced, and 28 had been initiated on ART at other 
healthcare facilities. Data from the remaining 749 children who 
fulfilled the inclusion criteria were analysed.
Baseline characteristics
Tables 1 and 2 describe patient and caregiver characteristics prior 
to ART initiation. One hundred and six children (14.5%) were 
commenced on ART in the ICU, 509 (68.0%) in the GMWs and 
127 (17.0%) in the OHCs. Seven hundred and thirty-two children 
(97.7%) would have qualified for expedited initiation of ART 
according to the 2013 South African national treatment guidelines 
(492 were aged <12 months, 129 were aged >12 months with CD4 
percentages <15%, and 111 were aged >12 months with WHO stage 
4 disease). Of these children, 182 (24.9%) were initiated on treat-
ment expeditiously, within 7 days of diagnosis. However, 367 (50.1%) 
were initiated within 7 days of hospital admission and a further 
198 (27.0%) within 14 days. Children commenced on ART in the 
OHCs were significantly older than those in the ICU and GMWs. 
Overall, 65.7% of all children initiated on ART were <12 months 
old. Children in the ICU and GMW cohorts had significantly lower 
median WAZ scores and more wasting. More than 75% of children 
had subnormal CD4 percentages of <25%, and 385 (51.4%) had 
CD4 percentages <15% and/or CD4 counts <200 cells/µL. More 
children in the ICU and GMW cohorts than in the OHC cohort 
Table 3. Primary diagnoses of children on presentation to hospital
ICU (N=106) GMWs (N=509)
Pneumonia 96 229
Gastroenteritis 5 137
Malnutrition 1 33
Septicaemia 1 14
PTB - 13
EPTB 1 19
Upper airway obstruction - 17
Meningitis 1 11
Non-accidental injury - 4
Surgical conditions 1 9
Other medical conditions - 23
PTB = pulmonary tuberculosis.
Table 4. CD4 percentage and VL responses after 6 months of ART
GMWs OHCs ICU p-value
CD4 percentage at 6 months, n (%) N=330 N=99 N=59 0.1
≥25 158 (47.9) 55 (55.6) 36 (61.0)
<25 172 (52.1) 44 (44.4) 23 (39.0)
CD4% change at 6 months, median % difference (IQR) N=320
4.7 (0.7 - 11.3)
N=91
3.2 (0.1 - 9.2)
N=54
9.1 (4.9 - 14.7)
0.001
VL (copies/mL) at 6 months, n (%) N=280 N=93 N=51
≤50 171 (61.1) 69 (74.2) 24 (47.1) 0.004
≤400 198 (70.7) 75 (80.7) 32 (62.8) 0.05
Log10 VL change at 6 months,* median % difference (IQR) N=216
–4.7 (–2.9 - –5.9)
N=90
–4.7 (–3.8 - –5.4)
N=39
–4.1 (–1.5 - –5.3)
0.35
IQR = interquartile range.
*Analyses of the differences between 6-month and baseline CD4% or log10 VL values in children with paired specimen results.
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had a baseline VL  >100 000 copies/mL. 
Younger children, particularly infants, pre-
sented with higher VLs. The median VL 
log10 value of children aged <12 months was 
6.0, while the median value for those aged 
>60 months was 4.8 (p=0.001). Overall a 
quarter of the children (24.7%) had current 
TB; of these, 6.5% had culture-confirmed 
disease and 19.2% probable TB. The times 
from HIV diagnosis and hospital admission 
to ART initiation were significantly shorter 
in the ICU cohort. No obvious differences 
were noted in caregiver characteristics prior 
to ART initiation. Most of the caregivers 
(92.9%) had at least one counselling session 
at RCWMCH, 53 (7.1%) receiving none. 
Not receiving counselling sessions was due 
to lack of caregiver availability during ART 
initiation (61.4%), patients being transferred 
out to other healthcare facilities before coun-
selling sessions could be initiated (10.3%), 
or counselling taking place during follow-up 
visits after discharge from hospital (17.2%); 
in 11.1% of cases there was no documenta-
tion of reasons why counselling sessions were 
not performed. Pneumonia was the predomi-
nant primary diagnosis, present in 90.6% and 
45.0% of children initiated on ART in the 
ICU and GMWs, respectively (Table 3).
Outcomes at 6 months
The Kaplan-Meier probability of overall 
mortality after 6 months of ART was 6.4% 
(95% confidence interval (CI) 4.9 - 8.4). 
Mortality at 6 months was significantly 
higher in the ICU cohort than in the GMW 
and OHC cohorts (Fig. 1, A). Among those 
who died, the median time to death after ART 
initiation was 25 days. Of the deaths in the 
GMW and ICU cohorts, 38 (90.5%) occurred 
during the primary hospital admission. Six 
children (3.1%) from the GMW cohort, 4 
(3.2%) from the OHC cohort and 4 (2.4%) 
from the ICU cohort were LTFU by 6 months 
after starting ART. No statistical differences 
were found in the probabilities of LTFU (log-
rank p=0.78) or attrition (log-rank p=0.12) 
between the three groups (Fig. 1, B).
After 6 months of ART, 51.0% of 
children remaining in care at RCWMCH 
had achieved a CD4 percentage of ≥25% 
and 62.3% a VL of ≤50 copies/mL. Paired 
analyses documented a significantly greater 
increase in median CD4 percentage over 
the first 6 months of ART among children 
initiated on ART in the ICU, with substantial 
declines in the median log10 VL values across 
all three treatment cohorts. The proportion 
of children achieving virological suppression 
was significantly lower in the ICU cohort 
(Table 4).
Of the 749 patients analysed, 257 were 
transferred out to primary healthcare 
facilities for continuation of care within 6 
months of ART initiation. Where possible, 
CD4 and VL results after transfer out were 
obtained from the Western Cape provincial 
laboratory database. Of those transferred 
out, 142 (55.3%) had CD4 count results 
and 109 (42.4%) had VL results available 6 
months after ART initiation. Paired analyses 
showed no significant differences in CD4 
or VL log values at 6 months in children 
who were transferred out compared with 
those who remained in care at RCWMCH. 
Median increases in CD4 percentage at 
6 months in those transferred out and 
those remaining in care were 4.0 and 5.8, 
respectively (p=0.165). Similarly, median 
decreases in VL log values at 6 months 
were 4.4 and 4.6, respectively (p=0.33), 
and there were no significant differences 
in the proportions of children achieving 
virological suppression. Of patients who 
were transferred out, 10 (3.9%) were LTFU 
and 9 (3.5%) died.
Predictors of mortality, attrition and 
an unsuppressed VL
On multivariable analysis, factors influencing 
mortality (Table 5) included age <3 months 
(adjusted hazard ratio (aHR) 1.8; 95% CI 
0.9 - 3.4), moderate and severe malnutrition 
(aHR 2.4; 95% CI 1.1 - 5.2 and aHR 3.2; 
95% CI 1.6 - 6.5, respectively), no caregiver 
counselling sessions before and during ART 
initiation (aHR 2.9; 95% CI 1.4 - 6.0), and 
starting ART in the ICU (aHR 2.6; 95% CI 
1.4 - 4.9). Children with caregivers who 
were not on ART at baseline had a decreased 
hazard of death (aHR 0.5; 95% CI 0.3 - 0.9).
Regression modelling of those children 
who were LTFU within 6 months of ART 
initiation revealed that age was the only 
variable associated with LTFU; children 
between the ages of 3 and 12 months had a 
3.16 increased risk of LTFU (p=0.02) com-
pared with older children.
Factors influencing attrition included 
patient age, WAZ scores, number of caregiver 
counselling sessions, and caregivers who 
were on ART at baseline. Older children aged 
between 13 and 60 months had a decreased 
hazard of attrition (aHR 0.5; 95% CI 0.2 - 1.1). 
Children who were severely malnourished 
and children who had caregivers who did 
not receive any counselling sessions were 
at increased risk of attrition (aHR 1.8; 95% 
CI 1.1 - 2.8 and aHR 2.6; 95% CI 1.4 - 5.0, 
respectively).
Age was a major predictor of an 
un suppressed VL (Table 6). Younger children 
were significantly less likely to achieve an 
undetectable VL. After 6 months on ART, 
35.8% of children <12 months of age and 
15.9% of those aged >12 months at the time 
of starting ART did not achieve a VL of 
<400 copies/mL. Furthermore, children <3 
months of age had a 3.1-fold increased risk 
of a VL of >50 copies/ml (95% CI 1.8 - 5.3), 
while children between 3 and 12 months 
of age had a 2.6-fold increased risk of a VL 
of >50 copies/ml (95% CI 1.3 - 4.9) after 
adjusting for other predictors of virological 
response. Similarly, children <3 months of 
age had a 3.0-fold increased risk of a VL of 
>400 copies/ml (95% CI 1.5 - 5.9), while 
children 3 - 12 months of age had a 2.6-fold 
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Fig. 1. Kaplan­Meier estimates for outcomes of (A) mortality (n=742) and (B) attrition (n=742) at 6 
months, according to ART initiation location.
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increased risk of a VL of >400 copies/ml 
(95% CI 1.4 - 4.6).
Discussion
Our study shows that ART-naïve HIV-
infected children are still very much at risk 
of HIV-related morbidity and mortality, 
particularly those who are <3 months old. 
The majority of children initiating ART at 
RCWMCH were <12 months old; 85.4% 
had WHO stage 3 or 4 disease and 75.7% 
were immunocompromised (CD4 percent-
age <25%) at presentation to hospital. These 
findings are consistent with a previous analy-
sis of infants <3 months old being initiated 
on ART across 20 clinics in Cape Town and 
Soweto, Johannesburg, SA. Advanced HIV 
disease was present in 62% of infants, sug-
gesting that even earlier initiation of ART is 
required to prevent mor bidity and mortal-
ity in young children.[13] Nevertheless, our 
study demonstrates that it was feasible to 
initiate ART rapidly after admission even in 
sick children, with mortality of 6.4% over-
all and <15% even in the sickest children 
who started ART in the ICU. In addition, 
LTFU was <5% among all groups of chil-
dren. While most children experienced 
immune recovery, the low proportion with 
virological suppression by 6 months after 
starting ART, especially among infants, is 
a concern.
Only 24.9% of all children who fulfilled 
the 2013 SA national treatment criteria 
for expedited initiation commenced ART 
within 7 days of diagnosis. This figure is 
low because ART initiation in our cohort 
preceded the 2013 recommendations. 
Diagnosis of 152 study children prior 
to hospitalisation at RCWMCH also 
contributed to delayed initiation. The 
proportions of children initiated on ART 
within 7 and 14 days of hospitalisation were 
49.0% and 75.4%, respectively, suggesting 
that not all hospitalised children who meet 
the criteria for expedited ART initiation will 
be commenced on ART within 7 days of HIV 
diagnosis.
A VL of <400 copies/mL was not achieved 
within 6 months of ART initiation in 
35.8% of children aged <12 months and 
15.9% of children aged >12 months, which 
is consistent with previous studies. Poor 
response in young children was described 
in a Soweto clinic, where the cumulative 
probability of achieving virological 
suppression (<400 copies/mL) 6 months after 
ART initiation was 59.4%. Children aged 
>36 months were more likely to achieve 
suppression at an earlier stage.[14] Failure 
to achieve virological suppression in young 
children may be attributed to several factors, 
including unpalatability of paediatric drug 
formulations, high baseline VLs in HIV-
infected infants requiring a longer period 
to suppress, and choice of first-line ART 
regimens.
Before the roll-out of ART in the public 
sector, a sizeable proportion of HIV-infected 
children required admission to ICU facilities. 
Mortality in these children was high, with 
rates of 27% and 44% recorded at RCWMCH 
and Tygerberg Hospital, respectively.[15] 
Since the introduction of ART, mortality 
in children has decreased substantially. 
Our study reports a 13.2% probability of 
mortality in children admitted to the ICU 
and subsequently commenced on ART, 
which although significantly higher than 
those in the GMW and OHC cohorts, is 
approximately half the pre-ART ICU mor-
tality. This reduction could be due to a 
combination of factors, including increased 
early HIV diagnosis and ART initiation in the 
ICU. Children requiring ICU care are more ill 
on presentation to hospital, which probably 
influences clinical, immunological and 
virological outcomes and possibly explains 
the increased mortality rate compared with 
the GMWs and OHCs. However, our results 
suggest that ART may have played a role 
in lowering ICU mortality. Other factors 
Table 5. Predictors of mortality during the first 6 months of ART
Univariate HR 
(95% CI) of 
mortality p-value
Adjusted HR 
(95% CI) of 
mortality 
(N=700) p-value
Age at ART initiation (months) 
(N=749)
<3 1.8 (0.95 - 3.4) 0.07 1.8 (0.9 - 3.4) 0.07
3 - 12 1.2 (0.7 - 2.1) 0.59 1
13 - 60 0.5 (0.2 - 1.2) 0.12 1
>60 1 1
WAZ categories (N=700)
Mild-normal 1 1
Moderate malnutrition 2.3 (1.1 - 4.8) 0.02 2.4 (1.1 - 5.2) 0.02
Severe malnutrition 2.5 (1.3 - 4.9) 0.008 3.2 (1.6 - 6.5) 0.001
Caregiver counselling sessions, n* 
(N=749)
0 3.8 (1.9 - 7.6) 0.0001 2.9 (1.4 - 6.0) 0.005
1 2.7 (0.7 - 11.1) 0.17 1
2 0.6 (0.1 - 4.1) 0.58 1
3 1 1
ART initiation location (N=742)
GMW 0.7 (0.4 - 1.2) 0.144 1
OHC 1 1
ICU 2.6 (1.4 - 4.9) 0.002 2.6 (1.4 - 4.9) 0.003
Caregiver support† (N=749)
Yes 1 1
No 1.0 (0.6 - 1.8) 0.95 1
Not available 2.5 (1.2 - 5.2) 0.013 2.4 (1.1 - 5.0) 0.02
Maternal ART at ART initiation 
(N=749)
Yes 1.1 (0.5 - 2.5) 0.762 1
No 0.5 (0.3 - – 0.8) 0.011 0.5 (0.3 - 0.9) 0.02
Not available 2.3 (1.3 - 4.3) 0.005 1
NA 1 1
HR = hazard ratio; NA = not applicable.
*Number of counselling sessions received by caregiver prior to or during ART initiation.
†Is there a second caregiver who is able to administer ART to the child in the event of the primary caregiver not being present?
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possibly leading to improved outcomes, but not assessed in our 
study, include increased awareness and experience in managing ill 
HIV-infected children, as well as improved treatment practices. A 
quarter of children presenting to RCWMCH were diagnosed with TB 
either before or during presentation to hospital. The majority were 
commenced on anti-TB treatment before ART initiation, consistent 
with WHO and national guidelines
Psychosocial factors contribute substantially to successful 
outcomes of ART, in particular counselling of caregivers before and 
during ART initiation. Our study demonstrates a greater than two-
fold increased risk of both mortality and attrition in the absence 
of caregiver counselling sessions. As most deaths occurred early 
during hospitalisation, absence of counselling is unlikely to have 
a causal effect on mortality. Indeed, caregiver unavailability was 
the major reason for caregivers not receiving counselling during 
ART initiation, reflecting the probable rapidity of ART initiation 
in these patients and the challenge of providing counselling when 
expediting ART.
Study strengths and limitations
A strength of this study lies in its novel contribution to the existing 
literature by examining the impact of ART initiation at different 
levels of healthcare in a tertiary hospital setting. It also provides an 
accurate reflection of healthcare function at an operational level in 
an overburdened healthcare system with a high turnover of patients.
Because this was a retrospective analysis, limitations in availability 
of routine data existed. Owing to a high transfer-out rate of children 
to other healthcare facilities after ART initiation, access to follow-
up clinical and laboratory data proved challenging. In particular, 
missing outcomes data impeded our ability to reflect accurately 
on growth patterns, immunological reconstitution and virological 
suppression in the original cohort of children initiated on therapy. 
In general, children who are transferred out are less ill than those 
remaining in care. Virological and immunological outcomes of the 
entire cohort initially started on ART could in fact have been better 
than reported, had complete follow-up data on those transferred out 
been available. The results of this study are not generalisable to the 
Table 6. Predictors of an unsuppressed VL after 6 months of ART
Univariate OR (95% CI) p-value Adjusted OR (95% CI) (N=338) p-value
Predictors of VL >50 copies/mL
Age at ART initiation (months) (N=429)
<3 1.6 (0.95 - 2.7) 0.078 3.1 (1.8 - 5.3) 0.001
3 - 12 2.4 (1.6 - 3.5) 0.001 2.6 (1.3 - 4.9) 0.005
13 - 60 0.6 (0.4 - 0.9) 0.029 1
>60 1 1
Caregiver support* (N=429)
Yes 1 1
No 0.6 (0.4 - 0.97) 0.039 0.5 (0.3 - 0.9) 0.013
Not available 0.7 (0.3 - 1.4) 0.298 1
Maternal ART at ART initiation (N=429)
Yes 0.8 (0.5 - 1.4) 0.433 1
No 1.7 (1.1 - 2.7) 0.012 1
Not available 0.4 (0.2 - 0.8) 0.009 0.4 (0.2 - 0.8) 0.011
NA 1 1
Predictors of VL >400 copies/mL
Age at ART initiation (months) (N=429)
<3 1.9 (1.1 - 3.3) 0.018 2.95 (1.5 - 5.9) 0.002
3 - 12 1.7 (1.1 - 2.7) 0.01 2.6 (1.4 - 4.6) 0.002
13 - 60 0.6 (0.4 - 1.1) 0.12 1
>60 1 1
Caregiver support* (N=429)
Yes 1 1
No 0.6 (0.4 - 0.97) 0.039 0.5 (0.3 - 0.9) 0.017
Not available 1.0 (0.5 - 2.3) 0.871 1
 Reported maternal HIV status at ART initiation 
(N=429)
Negative 1 1
Positive 1.8 (1.1 - 3.1) 0.024 1
Not available 0.4 (0.2 - 0.7) 0.005 0.3 (0.1 - 0.6) 0.002
OR = odds ratio; NA = not applicable.
*Is there a second caregiver who is able to administer ART to the child in the event of the primary caregiver not being present?
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entire HIV-infected paediatric population, as our cohort was a select 
group, admitted to a tertiary healthcare centre and having severe 
disease. Also, the study was restricted to children starting ART as this 
was its primary focus; this limits our ability to assess the feasibility of 
commencing ART in all severely ill children, some of whom may have 
died before treatment could be initiated.
Conclusion
These results highlight the importance of understanding the context 
in which children start ART when comparing outcomes in different 
settings, and demonstrate feasibility and good mortality outcomes 
in very ill young HIV-infected children. Similar studies at other 
tertiary hospitals should be performed in order to corroborate our 
findings and provide a basis for developing and optimising consensus 
guidelines for managing severely ill HIV-infected children.
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